Indiana University Vector Production Facility
Indianapolis, IN
National Center
38 confirmed programs
· 8 sponsors
· Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections
✓ Clinical Trials (38)
○ SEC Filings
○ Press
Quick Facts: Indiana University Vector Production Facility
- Signal Score
- 63.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Indianapolis, IN
- Modalities
- AAV, Lentiviral
- Active CGT Programs
- 38 confirmed from ClinicalTrials.gov across 8 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
38
Sponsors8
ModalitiesAAV, Lentiviral
38 active programs across 8 sponsors
Modalities: Lentiviral, AAV
12 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
View all 38 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability
68.0
Parent company: Indiana University
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Indiana University
SEC FilingsParent: Indiana University
Parent company: Indiana University
Financial assessment: 68.0/100
Capacity
58.0
1 CGT manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Clinical Activity 38 studies
NCT07168785
[18F]-AraG PET Imaging in LA HNSCC
EARLY_PHASE1
Not Yet Recruiting
NCT06725550
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
NA
Recruiting
NCT06915038
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
NA
Recruiting
NCT06508827
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
PHASE2
Withdrawn
NCT06513663
Exercise as Maintenance Therapy in Advanced Lung Cancer
NA
Recruiting
NCT05757843
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
PHASE2
Withdrawn
NCT05899166
Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes
NA
Recruiting
NCT06511453
Acupressure in Patients With Sickle Cell Disease
NA
Recruiting
NCT04402593
Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients...
NA
Withdrawn
NCT05783297
Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV...
NA
Active Not Recruiting
NCT05100342
Prospective Validation of a Points Score System Predicting 30-day Survival
NA
Recruiting
NCT05119036
Adjuvant Treatment Deintensification After Transoral Surgery for Human...
NA
Active Not Recruiting
NCT05251337
Use of Aromatherapy to Reduce Symptom Burden
PHASE2
Completed
NCT03321760
SABR for T1-2a N1 NSCLC
PHASE2
Withdrawn
NCT04930055
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
NA
Terminated
NCT05045820
Integrative Medicine in Pain Management in Sickle Cell Disease
NA
Active Not Recruiting
NCT04309370
Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate...
NA
Completed
NCT03997903
Imatinib for Pain in Sickle Cell Anemia
PHASE1/PHASE2
Terminated
NCT04187768
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
NA
Completed
NCT03789864
Biodynamic Imaging Utility in Predicting Response to Gemcitabine...
NA
Terminated
+ 18 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: